RespireRx Pharmaceuticals Inc (RSPI)

[oldstocks]

Lets get the word out, Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients

Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/35041859/

https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/

So I asked Ai Chat about RespireRx Pharmaceuticals KRM–II–81

Yes, you’re correctRespireRx Pharmaceuticals Inc. (Ticker: RSPI) is indeed working on a revolutionary new drug, KRM-II-81, for drug-resistant epilepsy patients12.
Here are some key points about KRM-II-81 and RespireRx’s work:
• KRM-II-81 is a novel a2/3 subtype preferring GABAA receptor potentiator2.
• It has shown very promising results in multiple animal models of treatment-resistant epilepsy and in human translational studies where it reduced epileptiform electrical signaling in brain tissue removed from treatment-resistant epileptic patients who underwent surgery3.
• In a case report, KRM-II-81 fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy2.
• KRM-II-81 has a preclinical profile predicting efficacy against pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain4.
• Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to hold seizure development in check4.
This is indeed a promising development in the field of epilepsy treatment. However, please note that this information is current as of the time of the search and may change over time. Always consult with a healthcare provider for the most accurate information.



I asked Ai Chat who makes drugs for Epilepsy.


There are several companies that are currently developing or manufacturing medications for epilepsy:
1. Marinus Pharmaceuticals has filed for Food and Drug Administration approval for its drug, Ganaxolone1.
2. The Canadian biopharmaceutical company, Xenon, is working on a treatment for adults with focal epilepsy1.
3. Cerevel Therapeutics is in a Phase 2 clinical trial with a drug that showed anti-epileptic activity in patients with photosensitive epilepsy1.
4. Stoke Therapeutics is developing a drug that aims to reduce the frequency of convulsive seizures in children with a rare form of epilepsy called Dravet syndrome1.
Additionally, the following companies are known to manufacture epilepsy drugs2:
• UCB S.A., Belgium
• Sanofi
• Pfizer, Inc.
• Otsuka America Pharmaceutical, Inc.
• Eisai Co., Ltd.
• Abbott Laboratories, Inc.
• Novartis AG
Please note that this information is current as of the time of the search and may change over time. Always consult with a healthcare provider for the most accurate information.